
Notas del episodio
On this week’s episode, we chat with Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and director of oncology at CureLab Oncology Inc., about elanagen, a promising therapeutic advance for women with platinum-resistant ovarian cancer; Eden Ben, CEO of Amorphical, about nano-amorphous mineral therapeutics inspired by blue crayfish; and Hans Schambye, CEO of BOOST Pharma, a company making progress in the battle with brittle bone disease.
Times:
03:36 Amorphical
26:26 CureLab Oncology
43:31 BOOST Pharma
CureLab Oncology
CureLab Oncology Inc. is a clinical-stage biotechnology company headquartered in the greater Boston area. The company is focused on developing safer, more effective treat ...
Palabras clave
biotech
biotechnology
cancer
oncology
brittle bone disease
mineral therapeutics
BOOST Pharma
cell therapy
Amorphical
CureLab Oncology
